References
- US Agency for Healthcare Research and Quality. Outcomes of sipuleucel-T therapy. Available at: https://www.cms.gov/determinationprocess/downloads/id77TA.pdf (Accessed Sept 21, 2011).
- Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411 - 22; http://dx.doi.org/10.1056/NEJMoa1001294; PMID: 20818862
- Goozner M. Concerns about Provenge simmer as CMS ponders coverage. J Natl Cancer Inst 2011; 103:288 - 9; http://dx.doi.org/10.1093/jnci/djr041; PMID: 21303996
- Longo DL. New therapies for castration-resistant prostate cancer. N Engl J Med 2010; 363:479 - 81; http://dx.doi.org/10.1056/NEJMe1006300; PMID: 20818868
- Hjelmgren J, Berggren F, Andersson F. Health economic guidelines--similarities, differences and some implications. Value Health 2001; 4:225 - 50; http://dx.doi.org/10.1046/j.1524-4733.2001.43040.x; PMID: 11705185
- Knopf K. Sipuleucel-T immunotherapy for advanced prostate cancer. Community Oncol 2010; 7:342 - 4
- Greenberg D, Earle C, Fang CH, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst 2010; 102:82 - 8; http://dx.doi.org/10.1093/jnci/djp472; PMID: 20056956
- National Institute for Health and Clinical Excellence. Appraising life-extending, end of life treatments. London, National Institute for Health and Clinical Excellence, 2009.
- National Institute for Health and Clinical Excellence. Update report on the application of the 'end-of-life' supplementary advice in health technology appraisals. London, National Institute for Health and Clinical Excellence, 2009.
- Chambers JD, Neumann PJ. Listening to Provenge--what a costly cancer treatment says about future Medicare policy. N Engl J Med 2011; 364:1687 - 9; http://dx.doi.org/10.1056/NEJMp1103057; PMID: 21470004
- Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare’s ‘coverage with evidence development’. Health Aff (Millwood) 2006; 25:1218 - 30; http://dx.doi.org/10.1377/hlthaff.25.5.1218; PMID: 16966717
- Brower V. Approval of provenge seen as first step for cancer treatment vaccines. J Natl Cancer Inst 2010; 102:1108 - 10; http://dx.doi.org/10.1093/jnci/djq295; PMID: 20668267
- Cook JP, Vernon JA, Manning R. Pharmaceutical risk-sharing agreements. Pharmacoeconomics 2008; 26:551 - 6; http://dx.doi.org/10.2165/00019053-200826070-00002; PMID: 18563946
- Krutoholow E, Nanavati A. Dendreon unlikely to develop diagnostic despite potential to allay reimbursement fears. Financial Times Aug 29, 2011.